Taysha Gene Therapies announced that the FDA granted both the rare pediatric disease and orphan drug designations to its investigational gene therapy TSHA-102 designed to treat Rett syndrome. The company is expected to file an investigational new drug application for the gene therapy in 2021.
Taysha gene therapy nabs orphan drug, rare pediatric tags
Sign up for Specialty Pharmacy SmartBrief
News affecting the specialty pharmacy industry
Get the intelligence you need: news and information that is changing your industry today, hand-curated by our professional editors from thousands of sources and delivered straight to your inbox.